stockrowBioMarin Pharmaceutical Inc. (BMRN) vs Halozyme Therapeutics, Inc. (HALO)
- BioMarin Pharmaceutical Inc. BMRN 55.60 −0.93%
- Halozyme Therapeutics, Inc. HALO 102.56 −16.59%
BioMarin Pharmaceutical Inc. and Halozyme Therapeutics, Inc. are both Biotechnology companies. Halozyme Therapeutics, Inc. is the larger, with a market value of $14.0B against $10.9B — 1.3× the size. BioMarin Pharmaceutical Inc. has negative trailing earnings, so its P/E is not meaningful; Halozyme Therapeutics, Inc. trades at 29.5×. Halozyme Therapeutics, Inc. grew revenue faster over the last twelve months: 45.0% against 18.1%. Halozyme Therapeutics, Inc. has the higher net margin (26.9% vs −0.52%) and the higher return on invested capital (19.9% vs 0.73%). Across the 20 metrics below, Halozyme Therapeutics, Inc. leads on 16 and BioMarin Pharmaceutical Inc. on 4.
Valuation
Profitability
| Metric | BMRN | HALO | Biotechnology median |
|---|---|---|---|
| Gross margin | 75.95% | 82.27% | 65.16% |
| Operating margin | 3.12% | 37.41% | 0.00% |
| Net margin | (0.52%) | 26.93% | 0.00% |
| Free cash flow margin | 15.26% | 49.84% | 0.00% |
| Return on equity | (0.31%) | 216.38% | (50.12%) |
| Return on assets | (0.20%) | 17.05% | (45.60%) |
| Return on invested capital | 0.73% | 19.87% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack